Wednesday, November 6, 2024

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

 Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLL


Two oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation compound (CDAC), BGB-16673


Oral presentation highlights continued deep and durable responses and manageable tolerability observed in Phase 1 study of BCL2 inhibitor, sonrotoclax, in combination with BRUKINSA for patients with treatment-naïve CLL/SLL


(BUSINESS WIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib), at the 66th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has 21 abstracts accepted at ASH 2024, with four selected for oral presentation.


“In the five years since its initial approval, BRUKINSA has become a standard of care for patients facing many B-cell malignancies, and our data featured at ASH demonstrated how long-term follow-up of treatment with BRUKINSA elicited deep and durable responses, including in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA is just the starting point – pipeline data for our BTK degrader BGB-16673 and BCL2 inhibitor sonrotoclax showcase our continued leadership across the hematology landscape and our commitment to bringing innovative medicines to as many people with cancer as possible.”


Presentations Highlight Sustained Progression-Free Survival and Deepening Durable Responses for Patients Treated with BRUKINSA in Treatment-Naïve and Relapsed/Refractory (R/R) Settings


Five-year follow-up results from Cohort 1 of the Phase 3 SEQUOIA study showed sustained progression-free survival (PFS) benefit with BRUKINSA in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with no new safety signals observed.


Results from the LTE (long-term extension rollover) study of patients with treatment-naïve and R/R CLL also showed that treatment with BRUKINSA as a single agent or as an investigational treatment in combination with obinutuzumab achieved high overall and complete response rates. With a median follow-up of up to 6.5 years, the responses were sustained, and no new safety signals were observed.


Results from an LTE study of patients with Waldenström macroglobulinemia (WM) from the Phase 3 ASPEN study, with a median follow-up of up to 5.8 years, demonstrated that treatment with BRUKINSA monotherapy remained durable and the safety/tolerability profile remained favorable.


Data from a Phase 2 study showed patients with prior intolerance to acalabrutinib were able to safely and effectively switch to BRUKINSA, with the majority of patients not experiencing recurrence of prior acalabrutinib-intolerance events while maintaining or deepening responses.


Pipeline Data Show Early Safety and Efficacy Across Multiple B-cell Malignancies


First-in-human Phase 1/2 CaDAnCe-101 presentations (two oral, one poster) highlighted generally manageable safety and promising efficacy results for BTK degrader, BGB-16673, in patients with R/R CLL/SLL, WM, and R/R indolent non-Hodgkin’s lymphoma. BGB-16673, which induces BTK degradation, is the first and most advanced asset from BeiGene’s chimeric degradation activation compound (CDAC) platform.


Oral presentation of the BGB-11417-101 Phase 1 study demonstrated B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax in combination with BRUKINSA continued to show promising efficacy and was generally well-tolerated in patients with treatment-naïve CLL/SLL; this combination is being evaluated in the Phase 3 CELESTIAL-TNCLL study (NCT06073821).


About BRUKINSA® (zanubrutinib)


BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.


BRUKINSA has the broadest label globally of any BTK inhibitor and is the only BTK inhibitor to provide the flexibility of once or twice daily dosing. The global BRUKINSA clinical development program includes about 6,000 patients enrolled in 30 countries and regions across more than 35 trials. BRUKINSA is approved in more than 70 markets, and more than 100,000 patients have been treated globally.


U.S. Indications and Important Safety Information for BRUKINSA (zanubrutinib)


INDICATIONS


BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with:


Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Waldenström’s macroglobulinemia (WM).

Mantle cell lymphoma (MCL) who have received at least one prior therapy.

Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.

The MCL, MZL and FL indications are approved under accelerated approval based on overall response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.


IMPORTANT SAFETY INFORMATION


Warnings and Precautions


Hemorrhage


Fatal and serious hemorrhage has occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher hemorrhage including intracranial and gastrointestinal hemorrhage, hematuria, and hemothorax was reported in 3.8% of patients treated with BRUKINSA in clinical trials, with fatalities occurring in 0.2% of patients. Bleeding of any grade, excluding purpura and petechiae, occurred in 32% of patients.


Bleeding has occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Coadministration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.


Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days before and after surgery depending upon the type of surgery and the risk of bleeding.


Infections


Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher infections occurred in 26% of patients, most commonly pneumonia (7.9%), with fatal infections occurring in 3.2% of patients. Infections due to hepatitis B virus (HBV) reactivation have occurred.


Consider prophylaxis for herpes simplex virus, pneumocystis jirovecii pneumonia, and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.


Cytopenias


Grade 3 or 4 cytopenias, including neutropenia (21%), thrombocytopenia (8%) and anemia (8%) based on laboratory measurements, developed in patients treated with BRUKINSA. Grade 4 neutropenia occurred in 10% of patients, and Grade 4 thrombocytopenia occurred in 2.5% of patients.


Monitor complete blood counts regularly during treatment and interrupt treatment, reduce the dose, or discontinue treatment as warranted. Treat using growth factor or transfusions, as needed.


Second Primary Malignancies


Second primary malignancies, including non-skin carcinoma, have occurred in 14% of patients treated with BRUKINSA. The most frequent second primary malignancy was non-melanoma skin cancers (8%), followed by other solid tumors in 7% of the patients (including melanoma in 1% of patients) and hematologic malignancies (0.7%). Advise patients to use sun protection and monitor patients for the development of second primary malignancies.


Cardiac Arrhythmias


Serious cardiac arrhythmias have occurred in patients treated with BRUKINSA. Atrial fibrillation and atrial flutter were reported in 4.4% patients treated with BRUKINSA, including Grade 3 or higher cases in 1.9% of patients. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher ventricular arrhythmias were reported in 0.3% of patients.


Monitor for signs and symptoms of cardiac arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea, chest discomfort), manage appropriately, and consider the risks and benefits of continued BRUKINSA treatment.


Hepatotoxicity, Including Drug-Induced Liver Injury


Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including BRUKINSA.


Evaluate bilirubin and transaminases at baseline and throughout treatment with BRUKINSA. For patients who develop abnormal liver tests after BRUKINSA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold BRUKINSA. Upon confirmation of DILI, discontinue BRUKINSA.


Embryo-Fetal Toxicity


Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity, including malformations at exposures that were 5 times higher than those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for 1 week after the last dose. Advise men to avoid fathering a child during treatment and for 1 week after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.


Adverse Reactions


The most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA (N=1729) are decreased neutrophil count (51%), decreased platelet count (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).


Drug Interactions


CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily.


CYP3A Inducers: Avoid coadministration with strong or moderate CYP3A inducers. Dose adjustment may be recommended with moderate CYP3A inducers.


Specific Populations


Hepatic Impairment: The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily.


Please see full U.S. Prescribing Information including U.S. Patient Information.


About BeiGene


BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s continued leadership in hematology and commitment to bringing innovative medicines to as many people with cancer as possible; the safety and efficacy of BeiGene’s pipeline assets; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20241105876184/en/



Permalink

https://www.aetoswire.com/en/news/0511202442672


Contacts

Investor Contact:

Liza Heapes

+1 857-302-5663

ir@beigene.com


Media Contact:

Kim Bencker

+1 610-256-8932

media@beigene.com


To access BeiGene media resources, please visit our News & Media site.

Tuesday, November 5, 2024

Vasion Unveils Output Automation: Revolutionizing Output Management and Workflow Automation with a Cloud-Native Solution

  (BUSINESS WIRE)--Vasion®, a pioneer in serverless printing and orchestrated automation, announced the release of Vasion Output Automation™, the cloud-native SaaS solution that automates output management, enabling customers with opportunities to leverage cutting-edge AI.

Vasion Output Automation can eliminate reliance on outdated, on-premise infrastructure with a modern serverless approach, allowing leaders to apply AI, preparing even highly regulated, security-intensive organizations for the future. The solution centralizes administrative control for both business-critical print and end user print from a single console, seamlessly integrating back-end systems, automating output, enhancing data accuracy, digital document conversion, and routing.

“Vasion Output Automation is the next big step for our customers in their digital transformation journeys. With our orchestration automation platform, we bring together print, output, document, and process automation into one cloud-native solution that can help any business truly automate its end-to-end operations. I believe this will revolutionize the way businesses will operate today,” said Vasion Chief Product & Technology Officer Corey Ercanbrack.

Vasion Output Automation is the leading product of the Vasion 2024 Fall Product Launch. The core benefits include:

  • Centralized Control and Reporting: The new Output Automation Console offers the flexibility to manage and troubleshoot document delivery directly from a centralized interface, streamlining operations and enhancing efficiency.
  • Continuity and Reliability: Up-level capabilities with a drag-and-drop rules engine, on top of the powerful workflow engine, to streamline print and workflow processes, and automate document management through rule-based processes to enhance efficiency and accuracy.
  • Cloud-Native Architecture: Eliminate costly on-premise print servers and centrally manage all critical document operations in the cloud, and enabling organizations to stay competitive by applying AI.

Additional Vasion Automate Product Innovations New this Fall:

Vasion Output Automation is part of the Vasion orchestrated automation platform, Vasion Automate. The Fall Launch also includes:

  • Web Print: Guests can print directly from their web browser through a web portal link, without installing any additional servers, drivers, agents, or involvement from admins. IT leaders stay in complete control of their printing environment while keeping it simple for guests to print.
  • Advanced Security: Enhancements include Off Network Cloud Print (ONCP) advancements, now fully supporting HP printers, mobile, and Chromebook devices.
  • Mobile Scan: Digitize documents on the go from mobile devices, send to multiple destinations, like email, or cloud storage providers.
  • AI-Enhanced Form Results: Simplify complex data analysis by using natural language to interface with form results, surfacing more insights, and delivering more impact from your data.

About Vasion:

Vasion revolutionized print automation with a cloud-native SaaS solution and is now a leader in intuitive orchestrated automation. Organizations can simplify their digital transformation using Vasion’s automation platform to integrate their print output with the digital work teams do today: capturing data, applying AI, OCR and ICR, building and automating workflows, digital signatures, universal content storage and search, built-in compliance controls, and cloud-based Output Automation™, combining end user print and output management. Vasion accelerates digital transformation by enabling leaders to leverage advanced integrations for AI, with robust security in a Zero Trust environment, and integrating, directing, and analyzing their automations through a single platform. PrinterLogic® and Vasion® are registered trademarks, and Vasion Automate™, Vasion Output Management™, and Vasion Print™ are trademarks of Vasion in the United States and/or other countries.

 



Contacts

 

Media Contact:
Nadia Romero
Sr. Manager of PR and Communications
nadia.romero@vasion.com


Telekom Srbija Extends Partnership with SES

  Multi-year contract renewal includes comprehensive satellite services to deliver SD and HD channels in the Balkan region

(BUSINESS WIRE) -- SES announced today that it has extended its contract with Telekom Srbija for another four years for satellite services from SES's ASTRA 3C satellite at 23.5 degrees East. This renewal reinforces a successful collaboration that began in 2011 with a first capacity agreement and expanded in 2018 with the launch of Telekom Srbija's DTH platform, M:Sat TV.

Under the agreement, SES will continue providing multi-transponder capacity to enable Telekom Srbija to deliver an SD and HD pay-TV channel offering across Serbia, Bosnia and Herzegovina, Montenegro and North Macedonia as part of its M:Sat TV platform. The agreement also includes uplink and backup services for transponders and redundant fiber connectivity for the entire platform.

“This comprehensive agreement with Telekom Srbija reinforces our position as an important satellite provider in the Balkans,” said Norbert Hölzle, Global Head of Media at SES. “Telekom Srbija's continued trust in our services demonstrates the enduring value of our satellite services and our ability to deliver premium content to audiences across a wide geographic area.”

“The extension of our relationship with SES ensures we can continue delivering high-quality entertainment to our subscribers across the region,” said Katarina Subotić, Chief Sales Officer at Telekom Srbija. “Their proven track record of reliable service delivery, combined with their dedicated sales and marketing support, makes them an ideal partner as we continue to grow our DTH platform.”

Follow us on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous orbit fleet and medium earth orbit (GEO-MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com

About Telekom Srbija

Telekom Srbija Group, with its headquarters in Serbia and operations across the region, is one of the largest telecommunications operators in Southeast Europe, with almost 11 million users. Telekom Srbija is a leading operator in fixed and mobile telephony, the Internet and multimedia spheres, both in Serbia and the region at large. We continuously transform ourselves and improve the satisfaction of our customers through the synergy of experience and new knowledge. We provide them with flawless connectivity and a superior digital experience at all times, which allows us to become their first choice in the markets where we operate. Further information is available at: www.telekomsrbija.com

 



Contacts

Suzanne Ong
Communications
Tel. +352 710 725 500
suzanne.ong@ses.com


Warner Bros. Discovery and SES Renew Multi-Year Deal to Broadcast SD and HD Channels in Germany and Austria

 


Viewers will continue to receive the Warner Bros. Discovery channels in both SD and HD quality via 19.2 degrees East


(BUSINESS WIRE) -- SES announced today that it has extended its partnership with Warner Bros. Discovery in a multi-year contract renewal. Under the agreement, SES will provide playout services and satellite capacity to deliver Warner Bros. Discovery’s SD and HD channels across Germany and Austria from SES’s prime video neighbourhood of 19.2 degrees East.


With this deal, Warner Bros. Discovery secures capacity for broadcasting the following channels unencrypted via satellite in SD: DMAX, TLC, Tele 5, Eurosport 1, and HGTV. In addition, the HD offerings of DMAX HD, TLC HD, Tele 5 HD, and Eurosport 1 HD will remain accessible through SES’s HD+ platform. The contracts for the Austrian DMAX and TLC channels have also been extended.


"A key to the success of our TV business is the reliable and extensive distribution of our channels and content across our key geographic markets," said Matthias Heinze, Managing Director / Head of Distribution & Partnerships at Warner Bros. Discovery. “This is why we highly value our trusted partnership with SES and look forward to our continued collaboration.”


"With its iconic brand and diverse content offering, Warner Bros. Discovery and its TV programming serve as a prime source of entertainment for many people,” said Norbert Hölzle, Global Head of Media at SES. “Thanks to our satellites at 19.2 degrees East and their direct reach of 18 million TV households in Germany and Austria, viewers will continue to receive their sports, entertainment, news and other programming in the best image quality for years to come."


Follow us on:


Twitter | Facebook | YouTube | LinkedIn | Instagram


Read our Blogs >

Visit the Media Gallery >


About SES


SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous orbit fleet and medium earth orbit (GEO-MEO) constellation of satellites, offering a combination of global coverage and high performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20241104458735/en/



Permalink

https://www.aetoswire.com/en/news/0511202442659


Contacts

Suzanne Ong

Communications

Tel. +352 710 725 500

suzanne.ong@ses.com

ewpartners Announces $50 Million Strategic Investment in Leshines to Localize Manufacturing in the Middle East

 RIYADH, Saudi Arabia - Tuesday, 05. November 2024 AETOSWire Print 



Leshines is the supply chain solution provider of Lenovo Group, which ranks among the top ten on Gartner’s prestigious Top 25 supply chain list.

The move reinforces ewpartners' and Leshine’s commitment to fostering local industrial growth and empowering enterprises in Saudi Arabia.


ewpartners (formerly eWTP Arabia Capital), the first international investment firm to establish a Saudi-Asia cross border platform, has announced a USD $50 million investment in Leshines, the supply chain solutions arm of Chinese multinational tech company Lenovo at The Future Investment Initiative (FII), a premier global platform that drives transformative investments and fosters international partnerships for sustainable economic growth.


The investment accelerates the localization of Leshines capabilities in Saudi Arabia, further strengthening the Kingdom’s position as a vital player in sustainable global trade networks and supply chain operations.


Five months ago, Lenovo and PIF-backed company Alat announced a strategic collaboration, including a proposed US$2 billion investment. Today, this partnership is set to advance to the next step.


Leshines is also exploring the option of entering the KSA-Sino Logistics Special Economic Zone at King Salman International Airport in Riyadh, an initiative which was announced by the Saudi Ministry of Transport and Logistics earlier this month. Managed by ewpartners, the Zone will cover a total area of 4 square kilometres and consist of a logistics industrial park, an international commercial and business park, and corresponding living space and facilities. It will enable international companies to manufacture locally in Saudi and then springboard their distribution to other markets worldwide. It is expected to attract over 3,000 wholesalers and retailers and around 200 light industrial manufacturers from China and Asia.


Jerry Li, Founder and Managing Partner at ewpartners said the following on the announcement:


"This investment is a significant step towards building the future of Saudi Arabia that we all envision, and we are actively working to establish this goal. Our investment in Leshines underscores our commitment to this project and our determination to foster local industrial growth and the development of Saudi enterprises. By partnering with Leshines to bring advanced supply chain solutions to Saudi Arabia and the MENA markets, we further assist Chinese companies in exploring localized production and empower local enterprises, aligning with the Kingdom’s Vision 2030."


Alan Zhou, COO of Leshines, commented on the announcement:


As Lenovo's smart supply chain solution platform, Leshines will take this opportunity to establish roots in Saudi Arabia, focusing on the MENA region, and build the foundational strategic capabilities of an advanced digital supply chain. As a globally leading strategic fund, ewpartners' strategic resources and unique advantages in KSA, the Middle East, and emerging markets perfectly match Leshines' strategic vision and development roadmap. With solid support and a strong partnership with ewpartners, we are confident that Saudi Arabia will become an important node in the Smart Supply Chain Platform, contributing to the Kingdom's Vision 2030.


The investment in Leshines marks the first transaction for ewpartners Fund II. Amid the growing synergy between China and the Middle East, ewpartners' investment model has garnered recognition from key stakeholders in the region. Supported by Saudi Arabia's sovereign wealth fund, ewpartners has also recently secured commitments from other GCC sovereign wealth funds, including USD 150 million from the Oman Investment Authority.


About ewpartners


ewpartners (formerly eWTP Arabia Capital) is an international investment firm specialising in cross-border investments between Asia and the MENA region. Backed by the Public Investment Fund (PIF), the firm has been active in Saudi Arabia since 2017 and was the first investment firm to launch a cross-border platform between the Kingdom and China.


Headquartered in Riyadh, ewpartners focuses on building value across borders by establishing strategic partnerships with exceptional companies. Our team's expertise in shaping innovative conducive policy frameworks can support governments in fostering economic transformation and diversification driven by innovation and technology.


ewpartners is committed to investing in, supporting, and growing successful businesses across the Asia and MENA regions, with a focus on key industries and themes such as digital infrastructure & solutions, advanced manufacturing & energy transition, and logistics & consumer enablement.


About Leshines


Lenovo Group is a global tech giant. For three consecutive years, Lenovo has ranked among the top ten on Gartner’s prestigious Top 25 supply chain list. As the strategic empowerment platform of Lenovo Global Supply Chain, Leshines is tasked with the important mission of driving supply chain transformation and upgrading through technological innovation. Drawing on Lenovo’s global industry strengths and management expertise, Leshines delivers digital international supply chain solutions tailored to the evolving needs of Chinese manufacturers expanding overseas.


About the KSA-Sino Logistics Special Economic Zone


The Special Economic Zone is a collaboration between ewpartners and the King Salman International Airport Development Company (KSIADC) and was announced on 13th of October 2024. The initiative is supported by the Ministry of Transport and Logistics and is one of several recently announced initiatives designed to strengthen supply chains and streamline trade, e-commerce and investment in line with the Kingdom’s Vision 2030. The project aims to create an integrated ecosystem that will encompass global enterprises, logistic facilities, supply chains, and high-end manufacturing, significantly bolstering Saudi Arabia’s regional and global distribution capabilities. International companies will establish manufacturing capabilities within the Zone and collaborate with Saudi enterprises to produce locally for distribution to markets around the world.


 



Permalink

https://www.aetoswire.com/en/news/ewp05112024en


Contacts

Vivian Chang


vivian@ewpartners.fund

AZA Finance subsidiary granted Payments Service Provider (PSSP) Licence in Nigeria

 


A longtime partner of Nigerian fintechs and banks, BT Payment Services Nigeria Limited is now licenced for naira payments and collections


(BUSINESS WIRE) -- Today, BT Payment Services Nigeria Limited (BT Payment) announced it has been granted a payments service provider (PSSP) licence by the Central Bank of Nigeria. It now offers Nigerian naira collections and payments to its customers in the Federal Republic of Nigeria.


BT Payment is a subsidiary of the global fintech AZA Finance, and is responsible for the group’s Nigeria corridor, helping corporates, fintechs, NGOs and other organisations transact in Nigerian naira.


Previously offering its fintech services through licensed Nigerian partners, now BT Payment can execute them directly, offering even faster and more affordable rates for its customers transacting in Nigeria.


“We've had the privilege of collaborating with many exceptional fintechs in Nigeria over the years, and are excited to join their ranks as a licenced payments service provider,” said Elizabeth Rossiello, CEO and founder of AZA Finance. “We are certain that this country and its currency will continue to be in-demand worldwide as more organisations and enterprises expand to the continent. We look forward to being a part of that growth and deepening our presence and commitment to Nigeria.”


This licence is the latest of several to be granted to the AZA Finance group since its founding more than 11 years ago, and marks the first of several expansionary announcements coming live by the end of 2024. Already this year, AZA Finance has continued to strengthen its pan-African and global footprint by adding Egypt, Cameroon, Zambia, Brazil, and India to its supported markets. These countries join Kenya, South Africa, Ghana, Senegal, Uganda, Botswana, Tanzania, Guinea, Morocco, New Zealand, China, Japan, Korea, the United States, Canada, the European Union, and the United Kingdom as available currencies and markets for the fintech’s suite of services. The company has also been extensively recognised this year for its success and leadership, having been named a semi-finalist for the prestigious Milken-Motsepe prize, listed in the top 5 inspiring workplaces in the Middle East and Africa by Inspiring Workplaces, and awarded the best use of technology in business payments by the Paytech Awards. Its CEO, Elizabeth Rossiello, was also named Fintech Leader of the Year by Fintech Awards London.


For businesses interested in learning more about AZA Finance and partnering with the company for payments, foreign exchange, treasury, or other financial services, its executives will be attending the Milken Middle East and Africa Summit, the Africa Financial Industry Summit (AFIS), and the UK-Francophone West & Central Africa Trade & Investment Forum (WCAF III) in December.


About AZA Finance


AZA Finance is a global payments and FX fintech. Founded in Nairobi in 2013, AZA makes it easier for companies around the world to exchange currencies, make payments, and settle easily in all major African and G20 currencies. Its secure and efficient API and web platform is a trusted gateway for leading remittance providers, multinational corporations, and innovative enterprises worldwide. Its mission is to power African trade and accelerate the growth of businesses across the continent. Visit azafinance.com for more information.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20241104765049/en/



Permalink

https://www.aetoswire.com/en/news/0511202442660


Contacts

Rachel@azafinance.com

Burjeel Holdings and Response Plus Medical launch $1mn Human Energy Health and Wellbeing Award

 Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, and Response Plus Medical Services (RPM), the largest pre-hospital care and emergency medical services provider in the region, have jointly launched the $1million Human Energy Health and Wellbeing Award at ADIPEC 2024 to boost workplace wellness across the global Energy sector.

The global energy sector has made significant strides in prioritising the health and wellbeing of its workforce. Building on this, Dr. Shamsheer Vayalil, Founder & Chairman – Burjeel Holdings, and Omran Al Khoori, Chairman – RPM Holding, announced the award during ADIPEC 2024, encouraging CEOs from major global energy organisations to further advance wellbeing across the industry.

The award focuses on initiatives using AI to enhance mental and physical health, features two categories. A $1million Wellbeing Investment supporting SMEs develop scalable health solutions. And an Excellence Recognition category celebrating large organisations for their innovative employee wellbeing initiatives.

The inaugural winners will be announced at ADIPEC 2025. Projects will be evaluated based on creating supportive workplace environments, demonstrating innovative approaches, and showing measurable impact.

Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, said: “The Energy sector, a cornerstone of global economies, has made significant strides in prioritising the physical and mental health of its workforce. As a trusted, long-standing healthcare partner to the sector, we believe it is our responsibility to foster a culture of holistic wellbeing across the sector. This award celebrates and inspires innovative and technology-driven solutions that address the diverse health challenges across some of the most challenging and rigorous work environments in the world.”

Omran Al Khoori, Chairman of RPM Holding, commented: “This award serves as recognition for companies and innovators coming up with new ideas to promote physical and mental wellbeing in the Energy sector. It is also a platform for translating ideas into concrete solutions that can reinforce workforce resilience in a critical global sector at a time when energy is undergoing a profound transformation.”

Aligning with ‘We the UAE 2031’ vision and the UAE National Wellbeing Strategy 2031, it reinforces the nation’s role as a hub for creating solutions to global challenges. The https://hewaward.com/ portal is now open for potential nominees. Further details on application dates and more will be shared later.



Permalink

https://www.aetoswire.com/en/news/0511202442674


Contacts

Jashmeh Bhagwagar, APCO


+971559548660


jbhagwagar@apcoworldwide.com